Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Watching the baseball playoffs this week, I was struck by the parallels between the Los Angeles Dodgers and Eli Lilly. Both franchises spend a lot of money and always appear to come out on top.
Original title: “Eli Lilly and the LA Dodgers: A tale of 2 dynasties”
A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.
Original title: “Argenx falls as Sjögren’s setback offsets celiac drug progress”
In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well.
Original title: “Beyond equity: Why venture debt is reshaping European biotech”
Big Pharma companies including Bristol Myers Squibb, Johnson & Johnson and Novartis are among those that made or planned layoffs in Q3. Those cuts could affect over 1,800 employees, with New Jersey the hardest-hit state.
Original title: “Q3 layoffs down YOY, with 90% fewer biopharma employees affected”
Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure funding to support the effort and will now pursue “strategic alternatives” instead.
Original title: “Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate”
A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.
Original title: “Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial”
Caribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from a handful of Big Pharma players, including Novartis, AbbVie and Pfizer.
Original title: “Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up”
The investment will equip Bayer to make oncology, cardiovascular and renal care ingredients and drugs.
Original title: “Bayer commits $2.2B to build pharma manufacturing plant in Ohio”
The person you expect to address the company’s problems should know the challenges your business faces. Not having that context will limit what they can accomplish.
Original title: “Why executive candidates need the truth, not the sales pitch”